Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Renal Cell 3Breast Neoplasms 2von Hippel-Lindau Disease 1Triple Negative Breast Neoplasms 1Sarcoma, Kaposi 1Sarcoma 1Neoplasm Metastasis 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Liposarcoma 1Leiomyosarcoma 1Kidney Neoplasms 1Hamartoma Syndrome, Multiple 1Glioma 1Glioblastoma 1Endometrial Neoplasms 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1Bone Neoplasms 1Autistic Disorder 1Astrocytoma 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 6Biopsy 6Doxorubicin 5pembrolizumab 4X-Rays 4Phantoms, Imaging 4Nuclear Medicine Department, Hospital 4Cyclophosphamide 4liposomal doxorubicin 3fludarabine 3ulixertinib 2tipifarnib 2tazemetostat 2selpercatinib 2palbociclib 2larotrectinib 2ivosidenib 2fludarabine phosphate 2ensartinib 2atezolizumab 2anlotinib 2Temozolomide 2Radiation 2Irinotecan 2Ifosfamide 2Carboplatin 2Bevacizumab 2trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Everolimus × 30 days × Clear all
NCT03114527 2026-05-22

Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma (DDL) and Leiomyosarcoma (LMS)

Fox Chase Cancer Center

Phase 2 Active not recruiting
48 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡